Response to the Comment by Suijkerbuijk et al. 'Survival of stage IV melanoma in Belgium and the Netherlands'

J Eur Acad Dermatol Venereol. 2022 Feb;36(2):e119. doi: 10.1111/jdv.17666. Epub 2021 Sep 30.

Authors

B Reyn¹, E Van Eycken², M Louwman³, K Henau², K Schreuder³, L Brochez⁴, M Garmyn¹, N A Kukutsch⁵

Affiliations

¹ KU Leuven University, Herestraat 49, Leuven, 3000, Belgium.
² Belgian Cancer Registry (BCR), Koningsstraat 215, Brussels, 1210, Belgium.
³ Netherlands Comprehensive Cancer Organisation (IKNL), Godebaldkwartier 419, Utrecht, 3511 DT, The Netherlands.
⁴ University Hospital Ghent, Corneel Heymanslaan 10, Gent, 9000, Belgium.
⁵ Leiden University Medical Centre (LUMC), Albinusdreef 2, Leiden, 2333 ZA, The Netherlands.

PMID: 34534376
DOI: 10.1111/jdv.17666

No abstract available

Publication types

Letter
Comment

MeSH terms

Belgium / epidemiology
Humans
Melanoma*
Netherlands / epidemiology

Grants and funding

Stichting Tegen Kanker